MedTrace Logo

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

NCT04122833 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-08-18

No results posted yet for this study

Summary

The concomitant co-mutation with epidermal growth factor receptor (EGFR) mutation might influence the clinical outcomes. The investigators will identify the impact of concommitant mutation on clinical outcome in patients with advanced -EGFR mutated adenocarcinoma.

The investigators will compare the genetic alterations between tumors of pre and post Tyrosin Kinase Inhibitor(TKI) treatments and predict the resistance mechanism for EGFR-TKIs by next-generation sequencing(NGS) analysis.

Conditions

  • Adenocarcinoma of Lung
  • EGFR Activating Mutation

Interventions

OTHER

Next generation sequencing

observational study

Sponsors & Collaborators

  • Roche Diagnostics GmbH

    collaborator INDUSTRY

  • Foundation Medicine

    collaborator INDUSTRY

  • Konkuk University Medical Center

    lead OTHER

Principal Investigators

  • In Ae Kim, MD. Ph.D · Kunkuk University Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2023-09-30
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04122833 on ClinicalTrials.gov